Synergistic benefits are not exclusive to one subtype of breast cancer as TNBC, HER2-positive, and hormone-positive breast cancer are all sensitive and susceptible phenotypes to statin combinatory therapy in vivo. This evidence concerns the gene ERBB2 and breast cancer.